Related Experiment Video

Updated: Jun 12, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

MiRNAs as biomarkers and therapeutic targets in cancer

Helen M Heneghan1, Nicola Miller, Michael J Kerin

  • 1Department of Surgery, National University of Ireland, Galway, Ireland.

Current Opinion in Pharmacology
|June 15, 2010
PubMed

Insights

MicroRNAs (miRNAs) are key regulators of gene expression frequently altered in cancer. These molecules show promise as biomarkers and therapeutic targets for personalized cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNA (miRNA) expression is frequently dysregulated in various cancers.
  • miRNAs represent a novel class of molecular factors influencing gene expression.
  • Their unique properties offer potential for cancer diagnostics and therapeutics.

Purpose of the Study:

  • To provide a comprehensive review of miRNA roles in cancer.
  • To discuss miRNA biogenesis, oncogenic/tumor suppressive functions, and biomarker potential.
  • To explore therapeutic applications and challenges of miRNA-based cancer strategies.

Main Methods:

  • Literature review of scientific publications on miRNAs in cancer.
  • Analysis of miRNA biogenesis pathways.
  • Evaluation of evidence for miRNA involvement in oncogenesis and tumor suppression.
  • Assessment of miRNA detection methods and clinical utility.
  • Review of preclinical and clinical studies on miRNA-targeted therapies.

Main Results:

  • miRNAs can function as oncogenes or tumor suppressors.
  • Specific miRNAs are dysregulated in common cancers like breast, prostate, lung, and colorectal cancer.
  • Circulating tumor-associated miRNAs show potential for early detection, prognostication, and management.
  • miRNAs possess characteristics (stability, specificity) suitable for biomarkers.
  • Therapeutic strategies targeting miRNAs are under development.

Conclusions:

  • miRNAs are pivotal in cancer development and progression.
  • miRNAs hold significant promise as sensitive and specific cancer biomarkers.
  • Targeting miRNAs offers a potential avenue for novel cancer therapies.
  • Overcoming challenges is crucial for translating miRNA research from bench to bedside.
  • miRNAs are expected to play a key role in individualized cancer management.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...